ClinicalTrials.gg
RecruitingNCT06078306Updated Apr 22, 2024

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

A Phase 2 interventional study of Azacitidine Injection and Venetoclax in B Acute Lymphoblastic Leukemia, Ph-Negative ALL and High Risk Acute Lymphoblastic Leukemia, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing venetoclax in Burkitt Lymphoma — 6 open to participants now, 11 under way, 1 of them phase 3. venetoclax · Burkitt Lymphoma.

Planned enrollment
11th of 13
20 · median 26
Started
2024
with 1 other
Phase 2
4 of 13
3 open now
Primary completion
2024-09
later than 2 of 10 live
Registered
9th of 13
by date
Lead sponsor
2 of 13
The First Affiliated Hospital of Soochow University

Among the 13 studies testing venetoclax in Burkitt Lymphoma, this one is the 11th largest by planned enrollment, is one of 2 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 2 of the 10 other live ones, and was the 9th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

6 of the 13 studies testing venetoclax in Burkitt Lymphoma are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing venetoclax in Burkitt Lymphoma, or all of them as a file.
02

Study summary

Clinical trial for the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in adult patients with newly diagnosed high-risk and Ph- B-ALL

Read the detailed description

To evaluate the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in Adult patients with newly diagnosed high-risk and Ph- B-ALL in this prospective, single arm study.

03

Conditions studied

  • B Acute Lymphoblastic Leukemia
  • Ph-Negative ALL
  • High Risk Acute Lymphoblastic Leukemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 and ≤65 years old
  2. Newly diagnosed and high risk B-ALL according to the 2022 WHO classification
  3. The immunophenotype of leukemia cells were CD19 and CD22 positive and Ph-;
  4. Anticipated survival time more than 12 weeks;
  5. Those who voluntarily participated in this trial and provided .

Exclusion criteria

Exclusion Criteria:

  1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
  2. shows prolonged , severe heart diseases such as severe arrhythmia in the past;
  3. Pregnant (or lactating) women;
  4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
  5. (HIV) positive; Active infection of virus or virus
  6. Previously treated with any CAR-T cell product or other genetically-modified T cell therapies;
  7. Creatinine>2.5mg/dl, or / AST > 3 times of normal amounts, or >2.0 mg/dl;
  8. Other uncontrolled diseases that were not suitable for this trial;
  9. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CAR-T therapy

    Therapeutic outcomes in adults with Ph- B-ALL have substantially improved in the last decade, with complete remission (CR) and long-term overall survival (OS) rates of around 90% and 40%-50%, respectively. The presence of measurable residual disease (MRD) is the strongest predictor of relapse in B-ALL. In this study, high risk Ph- B-ALL patients receive the induction chemotherapy with Azacitidine+Venetoclax. After induction chemotherapy with Azacitidine+Venetoclax (VA regime), each subject receives CD19CD22 CAR-T cells by intravenous infusion. The patients with MRD negative will undergo HSCT.

    Drug: Azacitidine Injection · Drug: Venetoclax · Drug: CD19CD22 CAR-T

Interventions

  • DrugAzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection

    Also known as: Azacitidine

  • Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral

    Also known as: ABT-199

  • DrugVenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion

    Also known as: GDC-0199

06

What researchers measure

Primary outcomes

  1. Complete Remission Rate

    MRD Negative Remission Rate after CD19CD22 cell therapy

    Time frame: The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was day 21 after CD19CD22 cells infusion

Secondary outcomes

  1. Complete Remission Rate of VA regime

    Complete Remission Rate after VA regime

    Time frame: The cycle of VA regime is day 21; Effect evaluation was day 7 after VA regime

  2. Complete Molecular Remission Rate

    Complete Molecular Remission Rate after CD19CD22 CAR-T cell therapy

    Time frame: The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was day 21 after CD19CD22 cells infusion

  3. Overall survival (OS)

    From the first infusion of CD19CD22 cells to death or the last visit

    Time frame: The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was 2 years after CD19CD22 CAR-T cells infusion

  4. Leukemia-free survival (LFS)

    Up to 2 years after CD19CD22 CAR-T cells infusion

    Time frame: The cycle of CD19CD22 cell therapy is day 2-4; Effect evaluation was 2 years after CD19CD22 CAR-T cells infusion

07

Study locations

1 of 1 sites recruiting
  • Xiaowen Tang
    Suzhou, Jiangsu 215000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Sep 2024, 4 months later.

Of 84 non-industry phase 2 interventional studies under Burkitt Lymphoma, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 4 months is below that.

Counting every sponsor, half of 92 studies reached it within 81 months; a quarter within 41 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Oct 11, 2023
StartEst.
Apr 20, 2024
Primary completionEst.
Sep 10, 2024
CompletionEst.
Sep 10, 2025
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06078306
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Apr 20, 2024 (estimated)
Primary completion
Sep 10, 2024 (estimated)
Completion
Sep 10, 2025 (estimated)
Last update
Apr 22, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Venetoclax

Start the discussion